

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name Nectin Therapeutics * Nectintx.com *

CEO name Fabian Tenenbaum*

- Nectin Therapeutics (NectinTx) is a clinical stage biotechnology company and a trailblazer in oncology drug development, with a focus on addressing unmet needs in cancer treatment. The lead product, NTX1088, is a first-in-class immune checkpoint inhibitor directed against PVR(NECL5), a novel target overexpressed in more than 50% of cancers. NTX1088 demonstrates superior standalone activity compared to existing immune checkpoint inhibitors (ICIs), and has the potential to enhance and revamp clinical response to existing therapies by invigorating the immune system to fight cancer.

NTX1088 is currently evaluated in leading cancer centers globally, as stand-alone and in combination with Keytruda in a phase I study. NTX1088 is safe, with no drug related SAEs seen in any of the patients. Preliminary efficacy across numerous hard to treat tumors is seen. NectinTx developed a diverse pipeline of first- and best-in-class therapies, including antibody-drug conjugates (ADCs) that are showing superiority over approved and clinically explored ADCs. These ADCs are developed in collaboration with world leading technology developers including LCB.

Nectin's dedication to innovation and excellence has earned recognition from prestigious organizations such as the Cancer Focus Fund, MD Anderson Cancer Center, and Merck MSD, who have funded and collaborated with the company to advance its phase 1 trial. The company's pipeline of novel and potent therapies has attracted investment from top investors in the field, including aMoon, Peregrine Ventures, IBF and GIBF.